[Mucoprotective drugs and aspirin-induced gastric injury].
Low-dose aspirin is widely used for anti-thrombotic strategy in the elderly. Despite the excellent benefits, GI bleeding due to gastric/duodenal ulcers or injury is a major complication in aspirin users. In animal model, low-dose aspirin induced gastric injury is prevented by the administration of proton-pump inhibitor(PPI), exogenous PGE2 and atropine. In clinical trials, PPI and famotidine (40 mg/d) are proven to have the preventive effect to gastric ulceration induced by low-dose aspirin use. Although gastric mucoprotective drugs including PG are speculated to show the preventive effect, the supportive clinical evidences are limited. Large-scaled, randomized clinical trials are required to confirm the clinical benefits of gastric mucoprotective drugs to low-dose aspirin induced gastric injury.
Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
Toshiro
T
Sugiyama
Hidemoto
H
Yamawaki
D000368:Aged; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects*; D015738:Famotidine / Q000627:therapeutic use; D006801:Humans; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D015738:Famotidine; D001241:Aspirin